Sionna Therapeutics, Inc.
SION- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002036042
In the last 90 days, Sionna Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 146 institutions reported holding it in 13F filings for Q2 2026, worth $2.12B in total; Viking Global Investors is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $31.4M in total
- 4
- 13F holdersQ2 2026, +25 vs. previous quarter
- 146
- 13F valueReported value at the end of Q2 2026
- $2.12B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding SION, Q2 2026
1 superinvestor reports holding Sionna Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
0.4%
Sionna Therapeutics, Inc.'s share of the portfolio
- Shares
- 3,195,181
- Value
- $140.6M
Latest insider trades
Open-market purchases and sales by Sionna Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 21, 2026 (view filing)6:56 PM ET | Sep 17 | 4 days | RA Capital Healthcare Fund LP and 5 othersDirector | SSale | −3.45M | $6.33 | −$21.8M | −50.0%3.45M after | 2 lots |
| Jul 9, 2026 (view filing)4:47 PM ET | Jul 7 | 2 days | Thompson Peter A.Director | SSale | −85.9K | $44.86 | −$3.85M | −3.4%2.47M after | 10b5-1Duplicate filing |
| Jul 9, 2026 (view filing)4:44 PM ET | Jul 7 | 2 days | OrbiMed Advisors LLC and 1 otherDirector | SSale | −85.9K | $44.86 | −$3.85M | −3.4%2.47M after | 10b5-1 |
| Jul 7, 2026 (view filing)4:38 PM ET | Jul 6 | 1 day | Fitzpatrick JenniferChief Legal Officer | SSale | −10.3K | $43.60 | −$446.9K | −100.0%0 after | 10b5-1 |
| Jul 2, 2026 (view filing)4:45 PM ET | Jun 30 | 2 days | Thompson Peter A.Director | SSale | −115.8K | $45.50 | −$5.27M | −4.3%2.56M after | 10b5-1Duplicate filing |
| Jul 2, 2026 (view filing)4:42 PM ET | Jun 30 | 2 days | OrbiMed Advisors LLC and 1 otherDirector | SSale | −115.8K | $45.50 | −$5.27M | −4.3%2.56M after | 10b5-1 |
| May 29, 2026 (view filing)8:57 PM ET | May 27 | 2 days | OrbiMed Advisors LLC and 1 otherDirector | SSale | −101 | $44.49 | −$4.49K | 0.0%2.67M after | 10b5-1Duplicate filing |
| May 29, 2026 (view filing) | May 27 | 2 days | Thompson Peter A.Director | SSale | −101 | $44.49 | −$4.49K | 0.0%2.67M after | 10b5-1 |
| May 11, 2026 (view filing)6:58 PM ET | May 7-11 | 4 days | OrbiMed Advisors LLC and 1 otherDirector | SSale | −293.0K | $45.62 | −$13.4M | −9.9%2.67M after | 3 lots10b5-1Duplicate filing |
| May 11, 2026 (view filing) | May 7-11 | 4 days | Thompson Peter A.Director | SSale | −293.0K | $45.62 | −$13.4M | −9.9%2.67M after | 3 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Sionna Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 9,905,045 | $435.7M | 3.79% | 00.0% | Unchanged |
| TPG GP A, LLC | 6,494,962 | $285.7M | 5.71% | 00.0% | Unchanged |
| Viking Global Investors LPSuperinvestorViking Global Investors | 3,195,181 | $140.6M | 0.40% | 00.0% | Unchanged |
| Atlas Venture Life Science Advisors, LLC | 2,995,602 | $131.8M | 14.95% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 2,555,877 | $112.4M | 2.13% | −974,825−27.6% | Reduced |
| Enavate Sciences GP, LLC | 2,478,030 | $109.0M | 31.56% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 1,600,000 | $70.4M | 0.10% | +1,450,000+966.7% | Added |
| BlackRock, Inc. | 1,474,769 | $64.9M | 0.00% | +178,902+13.8% | Added |
| JPMorgan Chase & Co | 1,490,508 | $64.1M | 0.00% | +25,494+1.7% | Added |
| Jennison Associates LLC | 1,172,133 | $51.6M | 0.03% | −279,087−19.2% | Reduced |